{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-033302","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2025-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.134458+00:00","generated_at":"2026-05-18T15:41:06.836690+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Stockholders approve 4.75M share increase to equity plan and new ESPP at annual meeting","bullets":["Amendment to 2017 Equity Incentive Plan adds 4,750,000 shares; approved by 53,046,229 votes for.","Employee Stock Purchase Plan approved: 650,000 shares authorized, purchased at 85% of lower of grant/ purchase price.","All eight director nominees elected; Steven Rubin received 12.4M withheld votes, others largely unanimous.","Crowe LLP ratified as independent auditor for FY2025 with 63.4M votes for.","Advisory say-on-pay proposal passed with 54.9M for vs 1.2M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-033302","json":"https://secwatch.observer/filing/0001628280-25-033302.json","markdown":"https://secwatch.observer/filing/0001628280-25-033302.md","text":"https://secwatch.observer/filing/0001628280-25-033302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828025033302/0001628280-25-033302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828025033302/cdxc-20250624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T15:41:06.836690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}